GlassScriptPhysician profile
Steven Santiago
NPI 1316080682
$289,607.82
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $34K · 2021: $24K · 2022: $27K · 2023: $42K · 2024: $23K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $11K · Food and Beverage: $7,227 · Consulting Fee: $300 · Education: $21.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,902.50 |
| Travel and Lodging | $11,042.98 |
| Food and Beverage | $7,226.78 |
| Consulting Fee | $300.00 |
| Education | $21.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $134,236.25 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Janssen Scientific Affairs, LLC | $117,532.84 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $30,437.19 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Theratechnologies INC. | $2,989.04 | 2021-2025 | Egrifta, Trogarzo |
| Janssen Products, LP | $2,640.00 | 2019-2020 | |
| Janssen Biotech, INC. | $817.82 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $348.35 | 2019-2025 | Delstrigo, Pifeltro, Capvaxive |
| Emd Serono, INC. | $323.33 | 2019-2025 | |
| Exact Sciences Corporation | $113.15 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $62.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Amgen INC. | $19.37 | 2023 | Repatha |
| Insulet Corporation | $16.38 | 2021 | |
| Napo Pharmaceuticals INC | $15.07 | 2019 | |
| Lilly USA, LLC | $14.27 | 2023 | Mounjaro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.77 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Santiago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.